STING1 and cancer: These interrelated and synergistic protective actions of STING agonists (summarized in Fig. 10) would seem to be of particular advantage for the treatment of metastatic bone cancer, which offers unique challenges due to the ongoing presence of systemic disease in conjunction with cancer-associated SREs and severe pain which can themselves increase cancer mortality48.